Cathie Wood’s ARK sells AMD stock, buys more Cerebras Systems

ARK disclosed a sizable rotation in its daily trades, buying 149,176 shares of Cerebras Systems for $46.4M while selling 35,033 shares of Teradyne for $12.5M, 59,009 shares of TSM for $24.6M, and 13,148 shares of AMD for $5.9M. It also trimmed biotech positions, selling 6,356 shares of CareDx and 16,065 shares of Twist Bioscience. The article is primarily a flow update and reflects Cathie Wood’s ongoing portfolio repositioning rather than a fundamental catalyst.

Analysis

The cleanest read-through is not “ARK bought one AI stock” but that it is reallocating from mature semiconductor exposures toward a higher-beta compute platform story. That matters because the sellers are all names where the market already has strong consensus ownership; incremental fund redemptions or factor de-risking can create outsized downside in crowded semis, while the buyer can keep levitating a smaller-cap AI infrastructure name with limited free float. In other words, the flow signal is more informative for TER/TSM/AMD than for the size of the purchase itself.

The near-term risk for the sold names is a reflexive momentum break: if one growth-tilted allocator is cutting exposure, systematic funds may treat that as confirmation that the AI trade is becoming more selective. TSM and AMD are especially exposed to this because they are often used as liquid proxies for the entire AI supply chain; a continued unwind there can pressure related equipment and foundry-adjacent names over a 2-6 week horizon even if fundamentals remain intact. TER is the most vulnerable on a relative basis because its demand is tied to capital intensity at the backend, which is exactly where investors start trimming when order visibility gets choppy.

The contrarian view is that this may be less bearish for semis than it looks and more a late-cycle rotation inside the same theme. If hyperscaler capex stays firm, then selling TSM/AMD could simply be funding a higher-variance AI beneficiary rather than signaling a macro downgrade. That creates a potential pair-trade setup: if the market extrapolates this as a wholesale semis cautionary signal, the high-quality liquid names may mean-revert faster than the smaller-cap winner, especially once the flow effect fades over days rather than months.

Key Decisions for Investors

• Short TER for 2-4 weeks versus SOXX hedge: best risk/reward if backend capex sentiment weakens; target a 6-8% downside, stop if the semicap index reclaims recent highs.
• Pair long CBRS / short AMD on a 1-2 month horizon: express the view that flow-driven upside in the smaller, less-owned AI name can persist while liquid mega-cap semis mean-revert; size modestly due to higher single-name volatility in CBRS.
• Reduce or hedge TSM exposure into strength over the next 1-3 sessions: use call spreads or collars rather than outright selling if core fundamentals remain constructive, since the main risk is crowding unwind rather than a thesis break.
• Fade AMD on rallies with tight risk controls: sell near-term call spreads or buy put spreads for a 2-6 week window; the setup is favorable if AI leadership narrows and investors penalize incremental de-risking.
• For biotech, prefer relative shorts in TWST/CDNA versus XBI only if broader risk appetite rolls over; otherwise treat the sales as low-conviction and avoid overfitting a small-flow signal.